Clinical Trials Logo

Clinical Trial Summary

This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in reducing central subfield thickness (CST) and improving best-corrected visual acuity (BCVA) in subjects with macular telangiectasia Type 1 (MacTel 1).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03669393
Study type Interventional
Source Oxurion
Contact
Status Completed
Phase Phase 2
Start date September 18, 2018
Completion date November 22, 2019

See also
  Status Clinical Trial Phase
Suspended NCT03940690 - Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease Phase 3